Kewaunee Scientific Corporation: Fiscal 2024 Third-Quarter Form 10-Q Summary
Business Context and Reporting Period
This unaudited Form 10-Q covers the three and nine months ended January 31, 2024, the Company’s fiscal 2024 third quarter and year-to-date period. Kewaunee designs, manufactures and installs scientific and technical furniture, laboratory cabinetry, fume hoods, workstations and related systems. Its Domestic segment primarily supports dealers and distribution partners, while its International segment provides laboratory design, engineering, construction and project-management services. The Company is a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended January 31, 2024 | Prior Year | Nine Months Ended January 31, 2024 | Prior Year |
|---|---|---|---|---|
| Net sales | $46.8 million | $60.8 million | $147.1 million | $165.5 million |
| Gross profit | $12.0 million | $10.3 million | $37.4 million | $25.2 million |
| Gross margin | 25.7% | 17.0% | 25.4% | 15.2% |
| Operating profit | $3.8 million | $2.3 million | $12.7 million | $2.7 million |
| Net earnings attributable to Kewaunee | $2.5 million | $0.7 million | $7.7 million | $(0.3) million |
| Diluted earnings per share | $0.85 | $0.25 | $2.64 | $(0.09) |
- Revenue mix: Third-quarter Domestic sales were $31.8 million, down 12.1%; International sales were $15.0 million, down 39.2%. Nine-month Domestic sales were $101.4 million, down 9.2%, and International sales were $45.7 million, down 15.3%.
- Profitability: Operating expenses increased to $8.2 million in the quarter and $24.7 million year to date. Operating expense ratios were 17.6% and 16.8% of sales, respectively, versus 13.2% and 13.6% in the comparable periods.
- Cash flow: Operating activities generated $18.4 million during the first nine months, compared with $3.5 million used in the prior-year period. Capital expenditures were $3.4 million.
- Liquidity: Cash and cash equivalents were $21.3 million at January 31, 2024, compared with $8.1 million at April 30, 2023. Including restricted cash, total cash was $27.1 million versus $13.8 million. Working capital was $54.0 million, with a current ratio of 2.3-to-1.0.
- Debt and financing: Revolving Credit Facility borrowings were approximately $3.0 million, with $9.3 million of remaining capacity, at a 9.57% borrowing rate. The Company was in compliance with its financial covenants. The sale-leaseback financing liability was $28.3 million, including $0.7 million classified as current.
- Backlog: Order backlog was $152.3 million at January 31, 2024, compared with $153.2 million at January 31, 2023 and $147.9 million at April 30, 2023.
Material Changes Versus the Prior Comparable Period
- Sales declined primarily because Domestic operations reduced non-product revenue after discontinuing direct sales to end users, while International sales benefited less from large project deliveries than in the prior-year period.
- Gross margin improved substantially, driven primarily by Domestic operations, improved manufacturing productivity, cost-containment actions and pricing of new orders to reflect higher raw-material costs.
- Net earnings improved despite lower revenue, reflecting stronger gross profit and lower non-controlling-interest deductions. The nine-month period moved from a $0.3 million attributable loss to $7.7 million of attributable earnings.
- Cash generation improved materially, supported by a $4.7 million reduction in receivables and a $6.2 million increase in deferred revenue, partially offset by a $3.8 million reduction in accounts payable and other accrued expenses.
- The Company repurchased 29,456 shares for approximately $0.8 million during the nine-month period, including 27,033 shares for approximately $0.7 million during the third quarter. Remaining authorization was 70,544 shares.
- Nine-month income tax expense included a one-time $0.4 million charge related to India tax matters after management discontinued management fees involving the Indian subsidiary. The nine-month effective tax rate was 33.1%, compared with 87.8% in the prior-year period.
Guidance, Outlook, Risks and Unusual Items
Management did not provide specific revenue or earnings guidance. It stated that demand remains difficult to predict because Kewaunee often acts as a subcontractor or supplier to dealers and subcontractors. Demand depends on laboratory construction activity, project timing, delivery schedules and prevailing project pricing.
Management believes the Company is positioned favorably based on improved organizational focus, a healthy backlog, improved manufacturing capabilities, a global management team and continued investment in laboratory-related end markets. It expects operating cash flow and the revolving facility to support ongoing requirements and capital expenditures during the current fiscal year.
- Key risks include customer-demand volatility, project timing, quarter-to-quarter operating fluctuations, raw-material and commodity-cost changes, supplier constraints, international operations and foreign-currency movements.
- Additional risks include economic and competitive conditions, legal and regulatory changes, government actions, natural disasters, war, terrorism and other force majeure events.
- The Company expects to contribute approximately $0.75 million to its defined-benefit pension plans in fiscal 2024.
- A new three-year lease, expected to commence in the second quarter of fiscal 2025, has aggregate future payments of $0.7 million that were not yet recorded on the balance sheet at January 31, 2024.
- The failed sale-leaseback financing arrangement carries a 20-year lease structure with initial monthly rent of approximately $0.2 million and annual increases of approximately 2%.
- Management reported effective disclosure controls and procedures and no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether the improved gross margins are sustainable after the benefit from productivity, cost containment and pricing actions.
- The timing and profitability of the $152.3 million backlog, particularly given lower current-period International sales.
- Whether reduced Domestic non-product revenue represents a durable business-model change and how it affects reported revenue comparability.
- Availability, interest rates and covenant compliance under the revolving credit facility, together with the $28.3 million sale-leaseback financing liability.
- The effect of the India tax matter, domestic valuation allowances and foreign tax rates on future effective tax rates and cash taxes.
- Future cash requirements for capital expenditures, pension contributions, lease obligations and the authorized share repurchase program.
- Exposure to raw-material prices, foreign-currency fluctuations, supplier constraints and customer project delays.